Investor Presentation Full Year 2021

24 Investor presentation Full year 2021 Continued single digit volume growth within the insulin segments globally Novo NordiskⓇ tMU Long-acting insulin Premix insulin Fast-acting insulin tMU tMU 250 CAGR volume1: 4.3% 100% 160 CAGR volume1: 1.1% 100% 240 MI penetration²: 78.7% MI penetration²: 48.6% CAGR volume1: 4.4% MI penetration²: 78.1% 100% 200 80% 80% 80% 120 160 150 60% 60% 60% 100 50 50 80 80 40% 40 20% 40% 80 60 20% 40% 20% 0 Nov 2016 0% 0 0% 0 0% Nov Nov Nov Nov Nov 2021 2016 2021 2016 2021 Ⓡ Segment volume Ⓡ Levemir Ⓡ -Tresiba Combined Segment volume -Ryzodeg Ⓡ -NovoMix® 30 -Combined Segment volume Ⓡ Fiasp NovoRapid Combined 1 CAGR for 5-year period 2 Includes new-generation insulin. tMU: Thousand mega units; NN: Novo Nordisk Note: Modern insulin (MI) penetration is of total segment, i.e. including animal and human insulin; Data is sensitive to changes in IQVIA data collection and reporting methodology. Source: IQVIA MAT, Nov 2021 volume figures

View entire presentation